Trial Profile

A Phase 1 Randomized, Placebo-Controlled, Blinded, Multiple Ascending Dose Study to Evaluate VIB7734 in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daxdilimab (Primary)
Indications Cutaneous lupus erythematosus; Dermatomyositis; Polymyositis; Sjogren's syndrome; Systemic lupus erythematosus; Systemic scleroderma
Focus Adverse reactions
Sponsors Amgen; Viela Bio

05 Nov 2020 Results published in Viela Bio Media Release.
05 Nov 2020 According to a Viela Bio media release, results selected for oral presentation in Late-Breaking Abstracts session during the virtual American College of Rheumatology (ACR) Convergence 2020.
12 Aug 2020 According to a Viela Bio media release, final data analysis expected to be completed in Q3 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com